Drug Patents owned by Cephalon
1. List of Fentora drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(1 year, 6 months from now) | |
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(1 year, 6 months from now) | |
| US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(5 years from now) | |
| US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(5 years from now) | |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET;BUCCAL, SUBLINGUAL
FENTORA family patents
14
United States
4
Japan
4
Argentina
3
Taiwan
3
China
2
Canada
2
Korea, Republic of
2
Brazil
2
Hong Kong
2
Germany
2
Spain
2
New Zealand
2
Australia
2
Norway
2
South Africa
2
Austria
2
Israel
2
European Union
1
ME
1
Poland
1
Slovenia
1
Ukraine
1
RS
1
Denmark
1
Croatia
1
Mexico
1
EA
1
Portugal
1
Cyprus
2. List of Nuvigil drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(5 months from now) | |
|
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(11 months from now) | |
|
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(1 year, 10 days from now) | |
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET;ORAL
NUVIGIL family patents
17
United States
8
China
8
European Union
6
Hong Kong
5
Japan
5
Spain
4
Canada
4
New Zealand
4
Australia
3
Korea, Republic of
3
Brazil
3
Taiwan
3
Malaysia
3
Argentina
3
Mexico
3
Norway
3
South Africa
3
Israel
2
France
2
Chile
2
Poland
2
Slovenia
2
Ukraine
2
Iceland
2
Germany
2
Denmark
2
EA
2
Austria
2
Portugal
2
Cyprus
1
Egypt
3. List of Provigil drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(5 months from now) | |
|
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(11 months from now) | |
Drugs and Companies using MODAFINIL ingredient
Market Authorisation Date: 24 December, 1998
Treatment: NA
Dosage: TABLET;ORAL
PROVIGIL family patents
7
United States
3
China
3
Japan
2
Canada
2
Korea, Republic of
2
Brazil
2
Hong Kong
2
Taiwan
2
Germany
2
Argentina
2
Spain
2
Mexico
2
New Zealand
2
Australia
2
Norway
2
South Africa
2
Austria
2
Israel
2
Malaysia
2
European Union
1
Poland
1
Slovenia
1
Ukraine
1
Iceland
1
Cyprus
1
Denmark
1
EA
1
Portugal
4. List of Treanda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(6 years from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(6 years from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 March, 2008
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell...
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic